دورية أكاديمية

Targeting the epigenetic machinery of cancer cells.

التفاصيل البيبلوغرافية
العنوان: Targeting the epigenetic machinery of cancer cells.
المؤلفون: Montenegro, M F, Sánchez-del-Campo, L, Fernández-Pérez, M P, Sáez-Ayala, M, Cabezas-Herrera, J, Rodríguez-López, J N
المصدر: Oncogene; 1/8/2015, Vol. 34 Issue 2, p135-143, 9p
مصطلحات موضوعية: CANCER cells, CELL growth, TUMOR suppressor genes, GENETIC regulation, CELL cycle, DNA methylation, CARCINOGENESIS
مستخلص: Cancer is characterized by uncontrolled cell growth and the acquisition of metastatic properties. In most cases, the activation of oncogenes and/or deactivation of tumour suppressor genes lead to uncontrolled cell cycle progression and inactivation of apoptotic mechanisms. Although the underlying mechanisms of carcinogenesis remain unknown, increasing evidence links aberrant regulation of methylation to tumourigenesis. In addition to the methylation of DNA and histones, methylation of nonhistone proteins, such as transcription factors, is also implicated in the biology and development of cancer. Because the metabolic cycling of methionine is a key pathway for many of these methylating reactions, strategies to target the epigenetic machinery of cancer cells could result in novel and efficient anticancer therapies. The application of these new epigenetic therapies could be of utility in the promotion of E2F1-dependent apoptosis in cancer cells, in avoiding metastatic pathways and/or in sensitizing tumour cells to radiotherapy. [ABSTRACT FROM AUTHOR]
Copyright of Oncogene is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:09509232
DOI:10.1038/onc.2013.605